Advanced Cell Technology announced today that it had enrolled the first patients in its two Phase I/II clinical trials, using retinal pigment epithelial (RPE) cells derived from embryonic stem cells (hESCs) for treating Stargardt’s Macular Dystropyy (SMD) and for the treatment of the dry form of age-related macular degeneration (Dry AMD). The first of twelve patients in each trial were enrolled at the Jules Stein Eye Institute at the University of California, Los Angeles (UCLA).
The two patients will be treated with immunosupressants for about a week before the RPE cells will be implanted.
Here is the full announcement:
(Read more...)
The two patients will be treated with immunosupressants for about a week before the RPE cells will be implanted.
Here is the full announcement:
(Read more...)